I-Mab Biopharma of Shanghai formed a process development partnership with WuXi Biologics to use WuXi Bio’s expertise for CMC development of at least five programs and commercial manufacturing of at least one program for its proprietary monoclonal antibody, bispecific antibody and fusion protein pipelines. The two companies said the agreement is a significant expansion of their current relationship. No financial details of the partnership were disclosed. I-Mab is developing novel biologics for immuno-oncology and auto-immune diseases.
Source: China Biotoday
